This bill creates a statutory mechanism in British Columbia to designate entire classes of drugs as "experimental" and to condition their clinical use and public funding on requirements set by the minister. It gives the minister authority to attach conditions to prescribing, dispensing and administering, and to require suppliers to accept contractual obligations before drugs can be used in the province.
For practitioners and health system managers, the bill represents a new gate: clinical discretion is preserved but tethered to administrative and commercial arrangements. For the supply chain, it signals that provincial access can be made contingent on accepting financial and reporting responsibilities chosen by government.
At a Glance
What It Does
The bill authorizes the minister to designate drug classes as experimental and requires that a wholesaler enter a minister‑approved risk management agreement before practitioners may prescribe, dispense or administer drugs in those classes. Those agreements must meet prescribed content requirements and the minister may impose conditions on monitoring, reporting and clinical use.
Who It Affects
Wholesalers and distributors of the affected drugs must enter into the agreements; practitioners cannot legally provide those drugs unless the agreement and ministerial conditions are in place. The designation also affects the inclusion of drugs in publicly funded programs and facilities licensed under provincial law.
Why It Matters
The measure shifts a layer of financial and administrative responsibility onto the supply chain rather than directly onto clinicians or the provincial treasury, which changes commercial risk calculus and could affect availability, procurement and pricing of designated drugs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act creates two linked tools. First, it establishes the statutory label "experimental drugs class" and gives the minister power to list specific classes and add others later, guided by criteria such as province‑wide prevalence and uncertainty about long‑term safety or effectiveness.
The bill names four initial categories — certain COVID‑19 vaccines, drugs used in harm‑reduction/safer‑supply programs, hormone treatments used for gender transition including puberty suppression, and SSRIs when prescribed for mental health — but the minister may expand the list by regulation.
Second, the Act ties clinical use and access to a commercial condition: a practitioner may not prescribe, dispense or administer a drug in a designated class unless the drug’s wholesaler has entered a risk management agreement that meets the minister’s standards. The minister can also set operational conditions for how those drugs are used, including monitoring and reporting obligations and restrictions that apply inside licensed health facilities.
Separately, the minister can make those agreements a precondition for a drug’s inclusion in provincial funding programs or for participation in government health initiatives.The bill specifies two central elements that must appear in the risk management agreements: the establishment and administration of a compensation fund to pay patients who suffer or face material risk of adverse health impacts from the drug, and an indemnity to the provincial government for defined health‑system costs tied to adverse impacts, long‑term outcomes or increased use of publicly funded services. The Lieutenant Governor in Council may prescribe the form and content of agreements and make regulations to implement reporting and other technical requirements.
The Act also contains a supremacy clause that gives it precedence over conflicting provincial enactments and comes into force by regulation.
The Five Things You Need to Know
The Act initially designates four classes as "experimental": mRNA and similar COVID‑19 vaccines used in the provincial program; drugs used in harm‑reduction/safer‑supply programs; puberty‑suppressing and other gender‑transition hormone treatments; and SSRIs prescribed for mental health.
The minister may add more classes using a discretionary test that can include province‑wide prevalence, uncertainty about long‑term safety or effectiveness, and potential for substantial health‑system costs.
A practitioner cannot prescribe, dispense or administer a drug in a designated class unless the drug’s wholesaler has signed a minister‑approved risk management agreement in the prescribed form.
Risk management agreements must require the wholesaler to create and run a compensation fund for patients who suffer or are at material risk of harm, and to indemnify the government for health‑system costs tied to adverse health impacts, long‑term outcomes, or increased use of public services.
The minister can require these agreements as a condition for a drug’s inclusion in publicly funded programs or for participation in government health protection initiatives, and may set monitoring and reporting requirements for wholesalers.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions and linkage to existing pharmacy law
Section 1 imports existing statutory terms (for example, "drug," "practitioner," and "wholesaler") from the Pharmacy Operations and Drug Scheduling Act. That choice narrows who the Act addresses: obligations fall on actors defined as wholesalers under provincial pharmacy law, not directly on manufacturers, prescribers or other commercial participants unless they meet that statutory definition. For compliance teams this matters: the legal target is the provincial wholesaler class.
Designation of experimental drug classes and criteria
Section 2 lists four initial classes that are automatically designated and gives the minister a broad discretionary power to add more. The minister may consider prevalence, uncertainty about long‑term safety or effectiveness, potential for significant health‑system costs and any other public‑health factor. Those criteria are loose and grant the executive considerable latitude to expand the list; procurement and clinical planners should expect the designation to be used dynamically rather than statically.
Prerequisites for clinicians: minister‑approved risk agreements and conditions
This is the operational core. It makes prescribing, dispensing and administering contingent on the wholesaler having a risk management agreement in the prescribed form that the minister finds satisfactory, and on compliance with any ministerial conditions. Those conditions can include monitoring and reporting by the wholesaler and other safeguards the minister deems necessary for public health. Practitioners remain the licensed clinicians making clinical decisions, but their legal ability to provide a drug in a designated class depends on administrative and contractual gates.
Link to public funding and licensed facilities
Section 4 lets the minister require a risk agreement as a precondition for a drug’s inclusion in provincially funded programs or for participation in public health initiatives. It also extends ministerial conditions to use inside health care facilities that are licensed or regulated under provincial law. That means procurement officers and facility administrators will need to coordinate with suppliers to ensure agreements are executed before public reimbursement or program participation is permitted.
Regulatory implementation: agreement form and technical rules
The Lieutenant Governor in Council may make regulations about the form and content of risk management agreements and other implementation details. The Act therefore sets policy principles and leaves granular design — who sits on compensation‑fund boards, claims procedures, caps or exclusions, timelines for reporting, standards of proof for causation — to regulation. That regulatory gap is where most of the practical implementation work will happen.
Supremacy and commencement
The Act includes a conflict provision saying it prevails over other provincial enactments to the extent of inconsistency, and it comes into force by regulation. The supremacy clause creates legal primacy within provincial law for these obligations, but it does not itself displace federal law or regulatory regimes.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients who suffer adverse effects: the bill mandates a dedicated compensation fund administered by wholesalers, creating an explicit recovery pathway that bypasses or supplements tort litigation.
- Provincial treasury and program managers: by enabling indemnities from wholesalers for certain health‑system costs, the government can limit direct fiscal exposure for adverse outcomes tied to designated drugs.
- Health system planners and public health officials: the minister’s authority to require monitoring and reporting creates centralized data flows that can help detect population‑level problems and guide policy responses.
- Advocacy groups focused on drug safety: the statutory framework institutionalizes a mechanism for accountability and redress, which gives patient advocates a concrete target (the compensation fund and agreement terms) to shape through regulation.
Who Bears the Cost
- Wholesalers and distributors: they must negotiate, fund and administer compensation schemes and provide indemnities, creating potentially large and uncertain financial liabilities and administrative burdens.
- Practitioners and facilities: clinicians cannot lawfully prescribe or administer designated drugs unless supplier agreements and ministerial conditions are satisfied, which may limit clinical options and impose administrative checks.
- Smaller or independent suppliers: firms without the capital to underwrite compensation funds or indemnities may be forced out of provincial markets, reducing supplier diversity and bargaining power for health authorities.
- Provincial regulators and ministries: the bill imposes a new oversight regime that requires staff time to review agreements, monitor compliance, adjudicate fund claims, and regulate technical details — work that may not be fully funded by the legislation itself.
Key Issues
The Core Tension
The central dilemma is how to balance patient protection and fiscal accountability with access and innovation: the Act shifts financial responsibility for rare or long‑term harms onto wholesalers to protect patients and the public purse, but doing so risks raising costs, narrowing suppliers, and complicating clinical access to therapies that regulators and clinicians deem beneficial.
The bill delegates most of the hard design work to the regulatory and ministerial level while imposing potentially open‑ended financial obligations on a defined class of commercial actors. The risk management agreement must contain a compensation fund and an indemnity for health‑system costs, but the Act does not specify claim standards, governance of the fund, caps or exclusions, time limits, or interactions with private insurance and tort claims.
Those gaps will determine whether the compensation fund functions as an efficient, fair remedy or as a litigation‑prone and administratively costly mechanism.
Another implementation tension lies in the choice of the wholesaler as the contracting party. Wholesalers may be intermediaries that lack control over manufacturing, labeling or clinical trial data; requiring them to carry financial liability can distort supply chains, reduce competition, or be passed through in higher prices.
At the same time, shifting liability away from clinicians and the provincial purse addresses political and fiscal concerns but risks creating access problems if suppliers decline to participate. The bill also centralizes broad discretionary power in the minister — from designation decisions to approval of agreement forms — which may produce regulatory uncertainty for industry and clinicians while providing flexibility to respond to emerging safety signals.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.